CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 14,340 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $20.60, for a total value of $295,404.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Shares of CytomX Therapeutics, Inc. (CTMX) traded down $0.24 on Wednesday, reaching $20.55. The company’s stock had a trading volume of 389,000 shares, compared to its average volume of 278,100. CytomX Therapeutics, Inc. has a 12 month low of $10.40 and a 12 month high of $24.67.

Institutional investors and hedge funds have recently made changes to their positions in the business. Macquarie Group Ltd. purchased a new stake in CytomX Therapeutics in the 3rd quarter valued at approximately $107,000. Legal & General Group Plc boosted its holdings in CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,434 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in CytomX Therapeutics in the 1st quarter valued at approximately $190,000. Cubist Systematic Strategies LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at approximately $174,000. Finally, Voya Investment Management LLC purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at approximately $203,000. 63.18% of the stock is currently owned by institutional investors.

A number of equities analysts recently issued reports on CTMX shares. Cowen reissued a “buy” rating on shares of CytomX Therapeutics in a report on Tuesday, August 8th. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a report on Tuesday, August 8th. BidaskClub raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. Bank of America reissued a “buy” rating and set a $30.00 price target (up previously from $28.00) on shares of CytomX Therapeutics in a report on Wednesday, August 9th. Finally, Jefferies Group set a $25.00 price target on CytomX Therapeutics and gave the stock a “buy” rating in a report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $31.88.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/cytomx-therapeutics-inc-ctmx-insider-sean-a-mccarthy-sells-14340-shares-of-stock/1747748.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.